Mobile

A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do...

Update Il y a 5 ans
Reference: EUCTR2008-000663-42

A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 μg o.d.) in patients with chronic obstructive pulmonary disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the safety of two indacaterol doses (150 and 300 μg o.d. via SDDPI) in patients with moderate to severe COPD as compared to placebo after 52 weeks of treatment.

Inclusion criteria

  • BPCO

Links